Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SCNX with free AI briefings, catalyst countdowns, and dilution alerts.

SCNX · Scienture Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.2M Cash on Hand
8.1mo Cash Runway
Follow SCNX by email Get an email when SCNX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SCNX, unsubscribe in one click. Privacy

📣 What SCNX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

SCNX holds $8.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 8.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCNX files for a raise →

👥 Who Owns SCNX

Insiders 100% Institutions (16 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Hariharan Shankar
Co-CEO & Chairman, Director, 10% owner
Insider 3,890,383 217.59% 2024-09-19
Mani Narasimhan
President & Co-CEO, Director
Insider 2,945,515 164.74% 2024-09-19
Surendra K Ajjarapu
Chairman and CEO, Director
Insider 210,103 11.75% 2024-01-05
Prashant Patel
Interim CFO and Director, Director
Insider 176,687 9.88% 2024-01-05
Eric Michael Sherb
Chief Financial Officer
Insider 50,000 2.80% 2025-12-31

Share count 1,787,953 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SCNX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCNX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.